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ABSTRACT
Phenotypic diversity associated with pathogenic
mutations of the human mitochondrial genome
(mtDNA) has often been explained by unequal seg-
regation of the mutated and wild-type genomes
(heteroplasmy). However, this simple hypothesis
cannot explain the tissue specificity of disorders
caused by homoplasmic mtDNA mutations. We have
previously associated a homoplasmic point muta-
tion (1624C`T) in MTTV with a profound metabolic
disorder that resulted in the neonatal deaths of
numerous siblings. Affected tissues harboured a
marked biochemical defect in components of the
mitochondrial respiratory chain, presumably due
to the extremely low (_1%) steady-state levels of
mt-tRNA
Val. In primary myoblasts and transmito-
chondrial cybrids established from the proband
(index case) and offspring, the marked respiratory
deficiency was lost and steady-state levels of the
mutated mt-tRNA
Val were greater than in the biopsy
material, but were still an order of magnitude lower
than in control myoblasts. We present evidence that
the generalized decrease in steady-state mt-tRNA
Val
observed in the homoplasmic 1624C`T-cell lines is
caused by a rapid degradation of the deacylated
form of the abnormal mt-tRNA
Val. By both establish-
ing the identity of the human mitochondrial valyl-
tRNA synthetase then inducing its overexpression
in transmitochondrial cell lines, we have been
able to partially restore steady-state levels of the
mutated mt-tRNA
Val, consistent with an increased
stability of the charged mt-tRNA. These data
indicate that variations in the levels of VARS2L
between tissue types and patients could underlie
the difference in clinical presentation between
individuals homoplasmic for the 1624C`T mutation.
INTRODUCTION
Diseases due to mtDNA mutation are a signiﬁcant cause
of human morbidity and mortality, but our understanding
of the factors that inﬂuence the presentation and course
of these diseases is far from complete (1,2). In particular,
the generally accepted explanation for phenotypic diver-
sity of mtDNA mutations is one of uneven segregation of
mutated and wild-type mtDNA to particular tissues, with
the resulting phenotype being dependent on this ratio or
total amount of wild-type mtDNA in these tissues. This
explanation is, however, often inadequate for heteroplas-
mic mutations and inapplicable to homoplasmic muta-
tions, where the same mtDNA genotype is shared between
virtually all molecules in all tissues. Homoplasmic
mtDNA mutations had generally been considered as
having low pathogenicity, with organ-speciﬁc phenotypes
(3–5). These mutations show incomplete penetrance and
are believed to cause disease in association with unknown
environmental or other genetic factors. Exceptions to this
rule are the homoplasmic mt-tRNA mutations, which
have now been identiﬁed in several individuals and
families (6–9).
We have previously described a family in whom
the homoplasmic 1624C4T MTTV (equivalent to
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Figure 1A) mutation underlies a devastating multi-
system disease (8). Brieﬂy, the proband in this family
(II-1) has histochemical, biochemical and molecular
biological evidence of mitochondrial disease but has only
mild disease with muscle weakness, fatigue and recurrent
migraines. She has one surviving aﬀected child (with
Leigh’s Disease) from 10 pregnancies by four diﬀerent
unrelated partners. Following her most recent pregnancy,
she gave birth to a female infant (III-10) who died in the
neonatal period from cardiomyopathy and lactic acidosis.
This infant had the same pathological ﬁndings in muscle
as her mother and the extremely low steady-state levels
of mt-tRNA
Val in cardiac and skeletal muscle conﬁrmed
that the 1624C4T mutation was pathogenic. This
mutation, although homoplasmic in all maternally related
family members, is clearly neither of ‘low pathogenicity’
nor is it organ speciﬁc, but probably is dependent on
polygenic factors for its phenotypic expression. One
candidate for such a factor is the cognate aminoacyl
synthetase. Elegant studies have shown that the pheno-
typic eﬀects of various pathogenic mt-tRNA mutations in
the yeast Saccharomyces cerevisiae can be suppressed by
over-expression of the cognate synthetase (10,11). Indeed,
the respiratory-deﬁcient phenotype caused by three
separate mutations in mt-tRNA
Leu were all suppressed
by over-expression of leucyl-tRNA synthetase, with
diﬀerent degrees of severity requiring diﬀerent levels of
expression for respiratory compensation (11).
Here, we report the establishment of homoplasmic
primary myoblasts and ﬁbroblasts plus a variety of trans-
mitochondrial cybrid cell lines all carrying the 1624C4T
transition. Although the steady-state level of the mutated
mt-tRNA
Val was not depleted to the vanishingly low
levels measured in mature skeletal muscle from the
patients (51% of control values), decreases of  90%
were detected when normalized to other mt-tRNA species
and compared to controls. This variability was unex-
pected, but may give an important clue to why the
mutation can lead to such variability in clinical presenta-
tion between patients. Hence, an investigation into the
underlying cause of this variability was undertaken.
The decrease was found to be due greatly to the reduced
stability of the deacylated mt-tRNA
Val C25U. Over-
expression of the cognate valyl synthetase, or inhibition
of mitochondrial protein synthesis, processes that would
be likely to result in the increased aminoacylation of
the mutated tRNA, resulted in partial restoration of the
mt-tRNA
Val levels. We suggest that relative expression
levels of VARS2L may underlie the tissue and patient
variability of this homoplasmic mt-tRNA disease.
Further, as the data show, levels of the aminoacylated
form can be artiﬁcially modulated, thus a potential
method for treating patients with this, or similar, disorders
could be considered.
METHODS
Tissue culture manipulations
All cells were grown at 378Ci n5 %C O 2 under humidiﬁed
conditions. Primary myoblast and ﬁbroblast cultures were
established from muscle or skin biopsy (II-1) or post-
mortem biopsy (III-10) using techniques described pre-
viously (12). Myoblasts were grown in Hams F10
(Invitrogen Ltd, Paisley UK) supplemented with 20%
(v:v) fetal calf serum, 1% (v:v) chick-embryo extract (ICN
Flow Biomedicals, High Wycombe, UK), 2mM
L-glutamine, 1 non-essential amino acids (NEAA),
Figure 1. Steady-state levels of mt-tRNA
Val are decreased in primary
cell lines from the patient and proband but do not show the
dramatically low levels evident in tissues. (A) Schematic representation
of the human MTTV gene sequence, highlighting the 1624C4T
mutation, corresponding to C25U substitution in the tRNA (http://
mamit-trna.u-strasbg.fr.) This mutation occurs in the D-stem of the
tRNA secondary structure that is predicted to weaken the interaction
with G10, a base pairing that has previously been shown to modulate
interaction with class I-type synthetases (27,28). (B and C) High-
resolution northern blots were performed on RNA isolated from
muscle homogenate (B) or myoblasts (C) of the proband (II-1),
oﬀspring (III-10) and two unaﬀected independent controls C1 and C2
from which myoblast cultures were. Diﬀerences in speciﬁc activity
of the various probes are normalized by calculating ratios of signals
for the mt-tRNA
Val and -tRNA
Phe species (B, upper panel) or
–tRNA
Leu(UUR) (B, lower panel; C) in each sample and comparing
these ratios between samples on the same blot. Ratios of mt-tRNA
levels in homogenate and myoblast sample are compared to C2 (B) or
C1 (C) that is set to 100% and are reported under each lane.
Representative experiments are shown. RNA was isolated from cell
lines on at least ﬁve separate occasions over a 2-year period. Variance
in ratios did not diﬀer by 42%.
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Fibroblasts were routinely grown in Eagle’s Minimum
Essential Medium (EMEM, Sigma) supplemented with
2mM L-glutamine, 1 NEAA, 10% (v:v) fetal calf serum
with streptomycin and penicillin as described above. In
one experiment, ﬁbroblasts were also grown in valine-
deﬁcient EMEM (Sigma-Aldrich Co.Ltd, Dorset, UK)
supplemented with 4mM L-valine.
Transmitochondrial cybrids were grown in Dulbecco’s
Modiﬁed Essential Media (DMEM, Sigma) supplemented
with 5% (v:v) fetal calf serum, 2mM L-glutamine with
streptomycin and penicillin. Cells devoid or depleted of
mtDNA were further supplemented by 50mg/ml uridine
and 1mM pyruvate.
Isolation of RNA andhigh-resolution northernblot analysis
TRIZOL Reagent (Invitrogen) was used to extract total
RNA from  200mg of skeletal and cardiac muscle and
from 1 to 2 10
6 cultured myoblasts or ﬁbroblasts. Large
RNA species were removed by precipitation with an equal
volume of 10M LiCl permitting subsequent precipitation
of smaller RNA molecules (5S and tRNAs) from the
resulting supernatant. The precipitated small RNAs were
re-suspended in a minimal volume of DEPC-treated dH2O
and 1mg aliquots were then electrophoresed through a
13% (w:v) 8M urea polyacrylamide gel and transferred
all as previously described (12). Separated RNA was
electroblotted onto a GeneScreen Plus membrane
(PerkinElmer, Beaconsﬁeld, UK) and ﬁxed by UV
irradiation. Regions of human mtDNA encoding the
genes for mt-tRNA
Leu[UUR], mt-tRNA
Phe and mt-
tRNA
Val were PCR ampliﬁed and puriﬁed (QIAquick
PCR puriﬁcation columns, Qiagen) to produce probes for
the blots. The human mt-tRNA
Leu[UUR] probe was
generated using the forward primer L3200 (positions
3200-3219) 50-TATACCCACACCCACCCAAG-30 and
reverse primer H3353 (positions 3353–3334) 50-GCGAT
TAGAATGGGTACAAT-30. The human mt-tRNA
Phe
probe was generated using the forward primer L552
(positions 552–570) 50-CCAAACCCCAAAGACACCC-30
and reverse primer H712 (positions 712–694) 50-GAAC
GGGGATGCTTGCATG-30. The human mt-tRNA
Val
probe was generated using the forward primer
L1579 (positions 1579–1598) 50-CTGGAAAGTGCA
CTTGGACG-30and reverse primer H1734 (positions
1734–1714) 50-GGGTAAATGGTTTGGCTAAGG-30.
Puriﬁed amplicons were radio-labelled with [a-
32P] dCTP
(3000Ci/mmol, GE Healthcare) using the random primer
method and unincorporated nucleotides removed by gel
ﬁltration through a Sephadex G-50 DNA grade column
(GE Healthcare, Amersham, UK). Membranes were
probed at 428C in hybridization solution [5 SSPE,
1% SDS, 10% (w:v) dextran sulphate, 50% (v:v)
formamide and 5 Denhardt’s solution] for 16h with
 1–2 10
6c.p.m. of each radiolabelled probe.
Membranes were then incubated at 428C for 16h. Where
appropriate, unlabelled amplicon was added to dilute the
speciﬁc activity of the probe. Post-hybridization, non-
speciﬁcally bound radiolabelled probe was removed by a
series of washes: 2 15min with 2 SSPE at room
temperature, 1 15min with 2 SSPE/2% (w:v) SDS.
Membranes were then placed in PhosphorImage cassettes
and subjected to ImageQuant (Molecular Dynamics, GE
Healthcare) analysis after a 24h exposure.
Invivo mitochondrial proteinsynthesis
Myoblasts were grown under the same conditions
described above on 35mm plates. Growth medium was
removed, the myoblasts rinsed with methionine-
free DMEM (Sigma) and placed in methionine-free
medium supplemented with 10% (v:v) dialysed FBS
(1000 MWCO; Sigma) containing 100mg/ml emetine
hydrochloride (Sigma) and incubated for 6min at 378C.
Radiolabelled [
35S] EasyTag methionine/cysteine (500mCi,
 1000Ci/mmol; Perkin Elmer), was then added and
the myoblasts incubated for 2h before washing,
re-suspension in PBS and dissolution in 50% (v:v)
sample buﬀer [0.125M Tris–HCl pH 6.8, 50% (v:v)
glycerol, 10% (w:v) SDS, 0.1% (w:v) bromophenol blue,
5% (v:v) b-mercaptoethanol]. Samples (20mg protein)
were loaded onto a 4–20% or 10–20% Tris–glycine pre-
cast gel (Novex; Invitrogen) and electrophoresed (20mA)
in standard Tris–glycine buﬀer. Following electrophoresis,
the gel was ﬁxed in 3% (v:v) glycerol, 10% (v:v) glacial
acetic acid, 30% (v:v) methanol for 1h, before drying at
608C. The gel was then placed in a PhosphorImage
cassette and ImageQuant analysis performed after a 16h
exposure.
mt-tRNA stability experiments
Six 75cm
2 ﬂasks of primary myoblasts were grown to
75–80% conﬂuency and fed with 20ml of culture medium
16–24h prior to the experiment. At time 0, ethidium
bromide was added directly to the medium to a ﬁnal
concentration of 250ng/ml. Cells were harvested at the
indicated time points and low molecular weight RNA was
extracted. Aliquots of the RNA were then electrophoresed
through a 4% (w:v) agarose gel for assessment of quality
and relative quantiﬁcation. Samples were fractionated
through a 13% polyacrylamide, 8M urea gel as described
earlier.
Production and visualization ofthe VARS2L-GFP fusion
protein
A 735-bp amplicon encoding the initiation codon and
N-terminal 232 residues of VARS2L ﬂanked by BamH1
restriction sites was generated by PCR with the KOD Hot
Start high-ﬁdelity polymerase (Novagen, Merck
Biosciences Ltd, Nottingham, UK), using the following
primers: 50 CACACAGGATCCTAATGTGCTCT
CTCTC 30 and 50-CTCTCTGGATCCTGCTCACAG
ATCTCTCC-30 and cDNA clone KIAA1885 (kindly
provided by the Kasuza DNA Research Institute, Chiba,
Japan) as template. This amplicon was conﬁrmed by DNA
sequence analysis and ligated in frame and upstream of
GFP in pGFP3 (pcDNA3.1 Invitrogen, containing the
GFP open reading frame and multiple cloning site). HeLa
cells were seeded onto coverslips and transiently trans-
fected with this fusion construct (5mg; SuperFect, Qiagen)
following the manufacturer’s recommendations. After
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Probes) was added to the growth media for 45min, prior
to washing and ﬁxing in 1% (v:v) paraformaldehyde
for 10min. The coverslips were mounted with Vectashield
(H-1200 containing DAPI for nuclear visualization,
Vector Laboratories Ltd, Peterborough, UK). Fluores-
cence was visualized with a Leica (Nussloch, Germany)
DMRA. Images were recorded using a cooled CCD
camera (Spot-2, Diagnostics Instruments) and imaging
system (MetaMorph 4.5, Universal Imaging Corporation,
Pennsylvania, USA).
Over-expression andpurification of human VARS2L
Various GST-fusion constructs were made by producing
and cloning the relevant amplicons derived from
KIAA1885 template cDNA into SalI–NotI linearized
pGEX-6P-1 (GE Healthcare) using the following forward
primers:
64 50-GCACCAGTCGACGCAAGTCACCTGCAGA
AT-30
78 50-GCACCAGTCGACCTACGAAACCCGGTG-30
92 50-GCACCAGTCGACTGCCTCCTGCATACAG
C-30
102 50-GCACCAGTCGACGATATGTTGAGGCTG
C-30
Amplicons were all generated by standard 35-cycle PCR
and KOD Hot Start polymerase (Novagen) using the
same reverse primer
50-CACACAGCGGCCGCTCAAAGACAGGTCTGA
G-30 and were NotI–SalI digested prior to ligation. The
resultant constructs were used to transform Escherichia
coli Rosetta(DE3)pLysS and fusion protein was expressed
(1mM IPTG) at 168C overnight. Soluble GST-VARS2L
fusion protein was aﬃnity puriﬁed using glutathione–
Sepharose 4B before release of the VARS2L by PreScis-
sion protease (GE Healthcare) following manufacturer’s
recommendations. Yield of soluble protein diﬀered depen-
dent on truncation size, but speciﬁc activities were similar.
Production of anti-VARS2L antibodies
As the cytosolic and predicted mitochondrial valyl syn-
thetase share common sequence elements, the use of full-
length VARS2L as antigen could not be considered.
Rabbit anti-sera were raised against two synthetic peptides
MVRDRQGRKMSKSLG and TARTPSEGEAGTQRQ
representing regions of primary sequence unique to the
putative mitochondrial protein and aﬃnity puriﬁed by
Eurogentec, Belgium.
Production of anmtDNA depletedHEK293 Flip-In T-Rex
cell line
HEK293 Flip-In T-Rex cells (Invitrogen) were seeded into
6-well plates in DMEM supplemented with 10% (w:v)
FBS, 50mg/ml uridine in the presence of 10mg/ml
blasticidin and 100mg/ml zeocin. Upon reaching 50%
conﬂuency, cells were treated with 100ng/ml ethidium
bromide and maintained in growth medium with ethidium
bromide for 4–6 weeks.
Generation ofHEK293 Flip-In T-REx
transmitochondrial cybrids
Cytoplasts for fusion with HEK293 Flip-In T-REx cells
were produced from 143B.206 transmitochondrial cybrids
homoplasmicforthe1624C4Tmutationbycentrifugation
on a Percoll isopycnic gradient as described by (13). In
short, 2 10
7 143B cybrids were re-suspended in 20ml 1:1
mixture of Percoll:DMEM containing 20mg/ml cytochala-
sin B and centrifuged at 44000g for 70min at 208C. All
cytoplasts were recovered, diluted with 10 vol of DMEM,
washed and re-suspended in DMEM. For fusion, cyto-
plastsweremixedwithmtDNA-depletedHEK293cellsina
1:1ratioandcentrifugedat1100gfor5mintoformapellet.
DMEM was removed and the cells re-suspended in 0.2ml
of 50% (w:v) polyethylene glycol 1500 (BDH Limited).
After 60s, DMEM (10ml) was added to the cells that were
then gently re-suspended and left to recover at 378C for
45min. Cells were then plated in DMEM supplemented
with 10% (v:v) FBS, 50mg/ml of uridine and 1mM
Na pyruvate at a variety of cell densities (5 10
3
–2 10
4
0/ml). After 24h, the medium was replaced with
DMEM supplemented with 10% dialysed FBS. To select
against any non-enucleated 143B donors, cybrids were
grown in 100mg/ml zeocin, 10mg/ml blasticidin S.
Production ofVARS2L-inducible cell lines
For inducible over-expression, a 3653bp EcoRV–NotI
containing the entire VARS2L open reading frame was
generated from the original Kazusa clone (KIAA1885)
and inserted into pcDNA5/FRT/TO (Invitrogen).
Constructs were isolated from transfectants and conﬁrmed
by restriction digest mapping and sequence analysis.
Stable and inducible transfectants were generated in
HEK293 Flip-In T-REx cells (Invitrogen) following com-
pany recommendations and selected for growth in hygro-
mycin B (100mg/ml). Crucially, the standard calcium
phosphate method of transfection was necessary, as the
use of other transfection reagents resulted in the loss of the
mutated mtDNA for unknown reasons. Individual clones
were expanded and inducible expression of VARS2L
(48h; 1mg/ml tetracycline) conﬁrmed by western analysis.
RESULTS
Primary cell lines homoplasmic forthe 1624C`Tmutation
harbour low mt-tRNA
Val levels
The level of mt-tRNA
Val in patient-derived muscle or
cardiac tissue homoplasmic for the 1624C4T mutation is
vanishingly low (51% of control) when normalized to
mt-tRNA
Phe [Figure 1A, or –tRNA
Leu(UUR) (Figure 1B
and C, and (8)], consistent with this mutation contributing
to the respiratory defect. Primary cell lines (myoblasts and
ﬁbroblasts) were established from the proband (II-1) and
from one of her aﬀected oﬀspring (III-10). As shown in
Figure 1, the steady-state level of mt-tRNA
Val was lower
than the comparable control lines, albeit that the dramatic
loss demonstrated in the patients’ tissue was not
recapitulated.
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the culture conditions, we assessed whether varying the
concentration of valine in the culture medium could mod-
ulate the steady-state level of mt-tRNA
Val in ﬁbroblasts.
Susceptibility to limiting valine concentrations (data not
shown) or to 10-fold higher valine concentrations than
standard (4mM, Figure S1) did not diﬀer between control
and patient ﬁbroblasts.
The profound biochemical defects associated with
the 1624C`Tmutation in tissueare notfound in
primary cell lines
The observation that the very low level of mt-tRNA
Val is
not recapitulated in the patient-derived cell lines prompted
the investigation of mitochondrial protein synthesis and
associated functions in the cultured cells. We ﬁrst assessed
the aminoacylation (charged) status of the remaining
mt-tRNA
Val. RNA was extracted under acidic (pH55)
conditions from cultured patient (III-10) myoblasts and
fractionated through a denaturing polyacrylamide gel.
High-resolution northern blots probed for speciﬁc
mt-tRNAs conﬁrmed the absolute amount of
mt-tRNA
Val was decreased; however, it also indicated
that the proportion of aminoacylated to deacylated
mt-tRNA
Val was increased [92% (III-10) versus 71%
(control) Figure S2]. To determine whether this level of
charged mt-tRNA
Val was suﬃcient in these cell lines to
allow for normal mitochondrial protein synthesis, the
incorporation of
35S-methionine into proteins synthesized
in mitochondria was evaluated in patient (III-10) and
control myoblasts. Although the 1624C4U mutation
disrupts a highly conserved residue and base pairing in the
stem of the dihydrouridine (DHU) loop of mt-tRNA
Val
secondary structure (http://mamit-trna.u-strasbg.fr), there
was no marked diﬀerence in mitochondrial protein
synthesis after either 30min (data not shown) or 120min
(Figure 2), consistent with the rescue in the patients
myoblasts of the profound decrease in complex I activity
noted in tissue homogenate (Table 1). Recovery of
complex IV activity also occurred, although to a lesser
extent. These data show that at least in cultured myoblasts
the normal steady-state level of aminoacylated
mt-tRNA
Val has a weak control strength in mitochondrial
protein synthesis.
The C25U mutation results inincreased turnover
of thedeacylated mt-tRNA
Val
The 1624C4T mutation led to a decrease in steady-state
level of mt-tRNA
Val. The decrease was not as profound as
in tissue homogenate from the patients and the remaining
mt-tRNA
Val was suﬃcient to facilitate normal mitochon-
drial protein synthesis. However, this variability in levels
could be a vital clue to understanding the variable
penetrance of this homoplasmic disorder. An investigation
was initiated into the lowered steady-state mt-tRNA
Val.
The mtDNA gene encoding tRNA
Val, MTTV is tran-
scribed as part of a polycistronic unit that includes the
tRNA
Phe gene, MTTF, therefore both mt-tRNA
Val and
-tRNA
Phe are encoded on the same RNA precursor
(14,15). As shown in Figure 1 and when compared to
other mt-tRNAs encoded on a separate polycistronic unit,
it is clear that the decrease is speciﬁc to mt-tRNA
Val.
Thus, the decrease may be due to the mutation causing
a more rapid turnover of the mutated mt-tRNA
Val.
We therefore compared the stability of mt-tRNA
Val in
Figure 2. Decreased levels of mt-tRNA
Val C25U could not be shown to
aﬀect mitochondrial protein synthesis. Myoblasts from patient and
control were grown in culture prior to in vivo mitochondrial protein
labelling as described in Materials and methods section and (29).
Following inhibition of cytosolic protein synthesis, radiolabelled
methionine/cysteine was added for 2h and whole-cell lysates (20mg
total protein) separated by SDS–PAGE. A representative
PhosphorImage is shown. Attribution of products is determined by
reference to 29.
Table 1. Biochemical analysis of mitochondrial enzymes from tissue
homogenates and myoblasts of patient and control samples
Sample Complex I/CS Complex II/CS Complex IV/CS
Muscle homogenate
Control (n=15) 0.240 0.060 0.320 0.088 1.340 0.390
Patient II-1 0.053 0.251 0.520
Patient III-10 0.023 0.327 0.244
Myoblasts
Control (n=3) 0.129 0.038 0.262 0.067 0.783 0.187
Patient III-10 0.089 0.185 0.295
Sample preparation and enzymatic assays were performed as detailed in
Materials and methods section. All respiratory complex activities are
ratioed to the activity of the mitochondrial matrix marker citrate
synthase.
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tion with ethidium bromide, a DNA intercalator that
can inhibit transcription of the mitochondrial genome.
Patient and control myoblasts were treated with ethidium
bromide (250ng/ml), before harvesting after the indicated
time points, RNA was extracted and the steady-state
levels of mt-tRNA
Val and mt-tRNA
Leu(UUR) were deter-
mined for each time point (Figure 3). Using this
concentration of ethidium bromide, the estimated half-life
of mt-tRNA
Val was considerably reduced in patients
III-10 and II-1 ( 3h and 3.75h, respectively), when
compared with controls (5.75h). The half-life of
mt-tRNA
Leu(UUR) did not vary signiﬁcantly between
control and patient II-1 but appears to be longer in
patient III-10 (424h). Whilst the mutated mt-tRNA
Val is
clearly being more rapidly degraded, the alteration in
calculated half-life (52–65% of control value) was
insuﬃcient to explain the substantially reduced steady-
state levels (510% of control value). At steady state,
tRNAs are present in both aminoacylated and deacylated
forms. To our knowledge, diﬀerences in the rates of tRNA
decay have never been reported to be dependent on the
charged state of the tRNA. However, it is possible that the
mutation may cause an alteration in tertiary structure,
leading to an increased susceptibility to decay. This may
be reduced both by interaction with the cognate synthe-
tase and by aminoacylation. Consequently, one possibility
to explain this discrepancy may be that mutated
mt-tRNA
Val is unstable until aminoacylated. This is
supported by the subtle increase in the aminoacylation
level of the mutated mt-tRNA
Val population (Figure S2).
To test this hypothesis, we treated the cells with
thiamphenicol, an inhibitor of mitochondrial peptidyl
transferase activity (16). As translation elongation is
inhibited, aminoacylated mt-tRNAs will be unable to
donate their amino acids to the growing peptide, resulting
in an increase in the amount of aminoacylated tRNA,
as has previously been described (17,18). Thus, by
inhibiting mitochondrial protein synthesis there should
be an increased level of all aminoacylated tRNAs and
consequently an elevation of mt-tRNA
Val at steady state.
As can be seen in Figure 4A, inhibition with thiamphe-
nicol (TAP) does indeed promote an increase in
mt-tRNA
Val steady-state levels, but only in the cell line
carrying the mutation. To further interrogate this
hypothesis, the cells were subjected to a second mitochon-
drial protein synthesis inhibitor, doxycycline (DOX,
Figure 4B), a derivative of tetracycline that inhibits
protein synthesis by preventing charged tRNA binding
to the A site in the mitoribosome. In agreement with this
hypothesis, a graded increase in tRNA levels was noted as
the concentration of DOX was increased to 10mM.
Verification that VARS2L isthe human mitochondrial
valyl-tRNA synthetase
If the deacylated form of mutated mt-tRNA
Val is indeed
more susceptible to degradation than either its aminoacyl-
ated form or its wild-type counterpart, it may be possible
to increase the steady-state level of mt-tRNA
Val by
increasing aminoacylation activity. As already described
in the Introduction section, over-expression of cognate
synthetases has been shown to rescue various mutated
mt-tRNAs in the yeast S. cerevisiae (10,11). Although
appealing, this approach was complicated at the outset of
these experiments by the absence of any reported
mitochondrial valyl synthetase. A simple bioinformatic
search revealed a strong candidate protein (KIAA1885/
VARS2L) containing the HIGH and KMSKS signature
motifs of the class I aminoacyl synthetases. The original
UNIPROT/TrEMBL entry (Q96QO2) failed to identify
an N-terminal methionine but a facile search revealed
Figure 3. Stability of mt-tRNA
Val C25U is impaired. To compare the
stability of mt-tRNA
Val in patients (II-1 and III-10) and control,
mitochondrial RNA synthesis was inhibited by the addition of ethidium
bromide (250ng/ml) and the remaining RNA was isolated at the
indicated time points. High-resolution blots were then performed with
probes speciﬁc for mt-tRNA
Val and –tRNA
Leu(UUR). Estimates for t1/2
were calculated by measuring pixel intensity for each mt-tRNA at each
time point. For each set of experiments, 5mg of low molecular weight
RNA was separated and equal loading conﬁrmed by reference to the
nuclear encoded 5S RNA (data not shown). For ease of comparison,
the speciﬁc activity of mt-tRNA
Leu(UUR) probe was decreased to allow
both signals to be visualized on the same blot and time course.
A representative time course is shown for RNA isolated from the three
cell lines.
Figure 4. Inhibition of mitochondrial protein synthesis partially
restores the levels of mt-tRNA
Val. Myoblast cell lines from the patient
(III-10) and control were treated with 50mg/ml of the mitochondrial
protein synthesis inhibitor thiamphenicol (+TAP, A), various concen-
trations of doxycycline (5 or 10mM, B) or untreated (–TAP, A or 0, B)
and RNA were isolated after 2 days. High-resolution northern blots
were probed for mt-tRNA
Val or –tRNA
Leu(UUR) and the relative level
of –tRNA
Val estimated by normalizing the ratio of the two signals for
the untreated controls.
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Strong mitochondrial import predictions were made
from MitoProt (www.ihg.gsf.de/ihg/mitoprot) and
TargetP (www.cbs.dtu.dk/services/TargetP), 82.2 and
87.9%, respectively. To conﬁrm mitochondrial localiza-
tion, a C-terminal GFP fusion construct was produced
and transient transfection revealed good co-localization
with the mitochondrial-speciﬁc marker Mitotracker Red
CM-H2XRos (Figure 5A). To purify the protein and
determine the aminoacylation activity of VARS2L,
various fusion constructs were made each with a short,
predicted N-terminal pre-sequence deletion. In all cases
irrespective of the background strain or conditions of
expression, only aggregated VARS2L could be made (data
not shown). To resolve these problems with aggregation,
more extensive N-terminal truncations of VARS2L fused
to GST were designed, ensuring that all predicted
functional domains were retained in the protein. All
constructs were expressed and soluble VARS2L puriﬁed
following removal of GST as described in Materials and
methods section (Figure S3). As initial template, human
mt-tRNA
Val was generated in vitro following the ribozyme
method outlined in Supplementary Methods and ref. 19.
Unfortunately, only minimal aminoacylation activity
above background activity could be detected using
tRNA produced from several independent assays (data
not shown). The majority of previous reports detailing the
function of mammalian mitochondrial synthetases have
used E. coli tRNA as substrates (20–23). Using the soluble
VARS2L carrying a 102 residue N-terminal deletion,
tritiated valine was successfully transferred to E. coli
tRNA
Val, albeit with a low aminoacylation activity
(1.2 0.2 10
 3 pmol aminoacylated tRNA/min/pmol
for VARS2L102, Supplementary Methods). Similarly,
low-level activity was noted for all other N-terminal
deletions (data not shown). To conﬁrm the activity was
indeed due to VARS2L and not to any remnant of
contaminating E. coli protein, activity was also noted with
enzyme immunoprecipitated from the reaction mix with
the anti-VARS2L antibodies prior to initiation of the
assay (data not shown).
Induction ofVARS2L results in increased steady-state
levelsof cognate mt-tRNA
Val 1624C`T
Recipient 
0 cell lines that have been used to generate
transmitochondrial cybrids are notoriously aneuploid and
data produced by uncontrolled over-expression of exo-
genous proteins in individual clones has to be interpreted
with great caution. Consequently, to show unequivocally
that over-expression of the synthetase could increase
aminoacylation of the mt-tRNA
Val and restore steady-
state levels, it was necessary to control expression of the
synthetase in any cybrid. To date, such an inducible
recipient 
0 cell line is not available. To tackle this
problem, the commercially available human cell line with
a deﬁned integration site that allows inducible expression
(HEK293 Flip-In T-REx) was subjected to long-term
culture in low-dose ethidium bromide to deplete cells of
endogenous mtDNA. Complete removal of mtDNA was
found not to be possible, although copy number was
depleted to51% of untreated controls (data not shown).
Cybrids were generated by fusion of these mtDNA-
depleted cells with cytoplasts derived from patient
ﬁbroblasts and selected as detailed in Materials and
methods section. DNA was isolated from the cybrids
and following RFLP analysis, three clones (clone 5, 11
and 17) containing 494% levels of 1624C4T were
retained. Similar to the cell lines homoplasmic for the
mutation, biochemical analysis of clone 17 revealed no
profound respiratory defect (data not shown). These three
cell lines were transfected with the full-length VARS2L-
encoding cDNA and stable, tetracycline inducible cell
lines were selected as detailed. To conﬁrm expression,
transfectants were expanded, induced and mitochondrial
extracts subjected to western analysis with anti-VARS2L
speciﬁc antibodies. As shown in Figure 5B, although the
endogenous levels of VARS2L were only just detectable,
even in large amounts of mitochondrial protein (100mg,
lane a), good induction was noted for each clone.
Following conﬁrmation of transfection, clone 17 was
expanded. The high level of heteroplasmy for the
1624C4T mutation was retained. Further, the steady-
state level of mutated C25U mt-tRNA
Val was conﬁrmed
to be lower than the wild type in HEK293 Flip-In
T-REx control cells as measured by high-resolution
northern blots (Figure 6). To determine whether the
over-expression of VARS2L could promote increased
mt-tRNA
Val, cells were initially induced for 3 days prior to
harvesting, RNA isolation and analysis by northern blot.
As shown in Figure 6A,  4-fold increase in mutated
Figure 5. VARS2L is a mitochondrial protein. (A) HeLa cells were
transiently transfected with a construct expressing the N-terminal 232
residues of VARS2L fused to GFP. Following transfection (24h), cells
were stained with the mitochondriotropic dye Mitotracker Red
CM-H2XROS. Transfected cells were visualized by ﬂuorescence
microscopy. Images were captured and mitochondrial co-localization
of the fusion protein was conﬁrmed by superimposition of the green
and red signals of a linescan of the image (dashed line visible on
image). An image typical of three independent transfections is shown.
(B) Transmitochondrial HEK293T Flip-in T-REx cybrids inducibly
expressing full-length VARS2L were produced as detailed in Materials
and methods section. Mitochondrial protein was isolated from control
HEK293T Flip-in T-REx cells (293) and the cybrid transfectants
(HEK1624 Clone 17) with (+) or without ( ) 48h of induction as
described in the Materials and methods section. Aliquots (100mg) were
subjected to western analysis using anti-VARS2L antibodies.
To conﬁrm equal loading of mitochondrial protein, an antibody to
mitochondrial ribosome recycling factor (mtRRF) was used.
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Val was apparent, increasing levels to almost
50% of the control HEK293 Flip-In T-REx line carrying
wild-type mtDNA. The control fusion of HEK293/
1624C4T that carried the mutation but were untrans-
fected and so could not express the cognate synthetase,
showed no increase in mt-tRNA
Val levels under identical
induction conditions (Figure S4), consistent with growth
of HEK293 Flip-In T-REx cells in 1mg/ml inducer for up
to 2 weeks having no measurable eﬀect on the rates of
mitochondrial protein synthesis (data not shown).
Further, over-expression of VARS2L in cybrid clones
retaining the 1624C genotype resulted in no apparent
increase of mt-tRNA
Val steady-state levels (Figure S5). A
more detailed time course also conﬁrmed an increase at 3,
5 and 7day post-induction (Figure 6B), consistent with the
over-expression of the mitochondrial valyl synthetase
partially suppressing the depletion of mt-tRNA
Val asso-
ciated with the 1624C4T mutation.
DISCUSSION
In this report, we show data that is consistent with the
pathogenic mt-tRNA
Val mutation causing a defect in
stability, which is partially protected by charging of
the mt-tRNA. We conﬁrm the identity of a human
mitochondrial valyl synthetase, VARS2L, that we show
is localized to mitochondria and can charge E. coli tRNA
with valine. Finally, we show that the depleted steady-
state level of the C25U mt-tRNA
Val can be partially
recovered by over-expression of the cognate mitochon-
drial synthetase. At the onset of these studies, there had
been no report of any candidate mitochondrial valyl
synthetase. However, in 2005, Florentz and colleagues (20)
reported a list of candidates for the remainder of the
uncharacterized human mitochondrial synthetases, which
they identiﬁed by database mining. This included refer-
ence to a diﬀerent form of VARS2L. Amongst the aims of
this current research, we wished to demonstrate and
conﬁrm mitochondrial localization of our version of
VARS2L and to determine whether it was a bona ﬁde
mitochondrial valyl synthetase, not to complete a full
biochemical characterization of this protein. Indeed, our
initial studies conﬁrmed co-localization and valyl synthe-
tase activity of this enzyme when using total E. coli tRNA
as substrate, albeit with very low speciﬁc activity. We were
unable to show any great eﬃciency of aminoacylation by
VARS2L with in vitro transcribed human mt-tRNA
Val as
substrate. However, it has been well documented that
mammalian mitochondrial synthetases are less eﬃcient
than their cytosolic or prokaryotic counterparts
(21,22,24). Further, full optimization of conditions had
not been performed for this enzyme. Lower activity with
mammalian in vitro transcribed mt-tRNA is also not
unusual (20–23). There are clearly cases where post-
transcriptional modiﬁcations are essential for robust
aminoacylation and in the absence of correct modiﬁca-
tions tRNAs have been shown occasionally to mis-fold
(25,26). Although not unexpected, the poor aminoacyla-
tion of the synthetic mt-tRNA
Val meant it was not
possible to compare the aminoacylation eﬃciencies of
the wild-type and mutated tRNA
Val substrates.
We conclude that it is the rapid decay rate of the
deacylated form of C25U mt-tRNA
Val, which is respon-
sible for its low steady-state level in all the primary and
transmitochondrial cybrid cell lines that we have gener-
ated and studied. This conclusion is based on the
following criteria: (i) shorter half-life of mt-tRNA
Val was
observed following inhibition of mitochondrial transcrip-
tion, (ii) inhibition of mitochondrial protein synthesis,
a condition likely to increase aminoacylation states
of all mt-tRNAs, led to increased steady-state levels
of C25U mt-tRNA
Val, (iii) the G10-C25 pairing in the
D-stem of tRNAs has been implicated in contacting
the cognate class I synthetases, suggesting mutations in
this pairing may result in decreased association/protection
(27,28) and (iv) over-expression of VARS2L promoted
an increase in C25U mt-tRNA
Val levels. Partial restora-
tion of mt-tRNA
Val levels by over-expression of VARS2L
was impressive but as no cell line containing the 1624C4T
substitution showed a profound defect in biochemical
Figure 6. Over-expression of human VARS2L can increase the steady-
state level of mutated mt-tRNA
Val.( A) HEK293T1624C4T clone 17
transfected cybrids, uninduced ( ) or induced (+) were grown for
3 days prior to isolation of RNA. High-resolution northern blots
were performed with probes to mt-tRNA
Val and –tRNA
Leu(UUR) as
indicated. Natural levels for both tRNA species are shown in the
control untransfected HEK293 cell line (293). Signal was quantiﬁed
by ImageQuant after PhosphorImager exposure and the ratio of
mt-tRNA
Val to –tRNA
Leu(UUR) given for each sample. (B) Extended
over-expression of VARS2L maintains the increased steady-state level
of mutated mt-tRNAVal. A similar experiment to (A) was performed,
with RNA isolated after the indicated induction time in days. Ratios of
the mt-tRNAs are shown for control untreated (293) and the
143B1624C4T homoplasmic cybrids (143B).
3072 Nucleic Acids Research, 2008, Vol. 36, No. 9activity of any mitochondrial respiratory enzyme, we have
limited this study to understanding the mechanisms
underlying the decreased stability of the mutated
mt-tRNA
Val. However, with reference to this diﬃculty
in recapitulating respiratory defects due to the
1624C4T mutation, it is interesting to note that we are
currently characterizing several independent 143B-based
homoplasmic 1624C4T transmitochondrial cybrid clones
that are unable to grow on galactose, consistent with these
clones being compromised for OXPHOS. This defect is
due to the aneuploid nature of the cybrids and amongst
several possibilities, may be caused by diﬀering steady-
state levels of the mt-tRNA
Val.
We have previously reported that this unique homo-
plasmic mutation in MTTV underlies a multi-system
disease aﬀecting three generations of a family. Despite its
homoplasmic nature, this mutation has an extremely
diverse clinical phenotype with at least one individual
remaining only mildly aﬀected. This diversity is not
reﬂected in the biochemical deﬁciency in muscle as in the
profound (III-10) and mildly aﬀected (II-10) individuals,
both showed severe defects in respiratory complex
activities. However, there may be variability in
mt-tRNA
Val levels in neuronal or cardiac tissue, which
may cause diﬀerences in mitochondrial protein synthesis
and consequently respiratory complex defects.
In summary, on the basis of the data provided in
this article, we propose the following hypothesis for the
variable eﬀects of the 1624C4T MTTV mutation. Steady-
state levels are a result of the rate of tRNA production
(synthesis, processing, maturation) minus the rate of
decay. This mutation causes an increased decay rate of
the deacylated form, which is oﬀset in part by aminoacy-
lation. We predict that the dramatic diﬀerences in steady-
state levels is due to natural variabilities in the rates
of synthesis and decay of the deacylated mutant form in
a given cell type and the relative amounts of valyl
synthetase available to promote increased aminoacyla-
tion and therefore increased stability. This hypothesis
predicts that although these rates will vary between
tissues, over-expression of VARS2L within a tissue will
always increase the level of charged mt-tRNA
Val steady-
state levels, potentially restoring mitochondrial protein
synthesis. Testing this hypothesis may lead to a greater
understanding of the pathophysiology of mitochondrial
disease and to formulating novel therapeutic approaches
for these devastating disorders.
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